Altre lingue PharmaTher Holdings Ltd.

Azioni

PHRM

CA71716H1082

Mercato chiuso - Canadian Securities Exchange Altri mercati azionari 21:59:59 08/05/2024			Variaz. 5gg	Var. 1 gen.
0,26 ^CAD	-1,89%		-5,45%	-17,46%

23/04	PharmaTher Holdings Ltd. Riporta i risultati degli utili per il terzo trimestre e i nove mesi conclusi il 29 febbraio 2024	CI
16/04	PharmaTher Holdings Ltd. Fornisce un aggiornamento della sua domanda prioritaria originale abbreviata di nuovi farmaci per la ketamina	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia	01/05
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine	01/05
PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	23/04
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	18/04
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Provides Update For PD-001	21/02
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia	21/02
CapitalGainsReport: Foreign Stocks Under .2 With Growing Potential (TBRIF, BRHCF, FFNTF, PHRRF)	15/02
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	12/02
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	27/01
PharmaTher Provided Update for Expected FDA Approval of Ketamine	10/01
PharmaTher Provides Update for Expected FDA Approval of Ketamine	10/01
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	10/01
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	31/10/23
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	29/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue PharmaTher Holdings Ltd.

Azioni

PHRM

CA71716H1082

Altre lingue

Filtri